INCR
Price
$1.42
Change
-$0.02 (-1.40%)
Updated
Dec 18, 04:59 PM (EDT)
110 days until earnings call
SUPN
Price
$35.38
Change
-$0.84 (-2.32%)
Updated
Dec 18, 04:59 PM (EDT)
76 days until earnings call
Ad is loading...

INCR vs SUPN

Header iconINCR vs SUPN Comparison
Open Charts INCR vs SUPNBanner chart's image
Intercure
Price$1.42
Change-$0.02 (-1.40%)
Volume$100
CapitalizationN/A
Supernus Pharmaceuticals
Price$35.38
Change-$0.84 (-2.32%)
Volume$2.53K
CapitalizationN/A
INCR vs SUPN Comparison Chart
Loading...
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCR vs. SUPN commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCR is a StrongBuy and SUPN is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (INCR: $1.43 vs. SUPN: $36.22)
Brand notoriety: INCR and SUPN are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: INCR: 96% vs. SUPN: 90%
Market capitalization -- INCR: $123.5M vs. SUPN: $1.84B
INCR [@Pharmaceuticals: Other] is valued at $123.5M. SUPN’s [@Pharmaceuticals: Other] market capitalization is $1.84B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.53B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCR’s FA Score shows that 1 FA rating(s) are green whileSUPN’s FA Score has 0 green FA rating(s).

  • INCR’s FA Score: 1 green, 4 red.
  • SUPN’s FA Score: 0 green, 5 red.
According to our system of comparison, SUPN is a better buy in the long-term than INCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCR’s TA Score shows that 5 TA indicator(s) are bullish while SUPN’s TA Score has 3 bullish TA indicator(s).

  • INCR’s TA Score: 5 bullish, 2 bearish.
  • SUPN’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, INCR is a better buy in the short-term than SUPN.

Price Growth

INCR (@Pharmaceuticals: Other) experienced а +2.88% price change this week, while SUPN (@Pharmaceuticals: Other) price change was -1.42% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.61%. For the same industry, the average monthly price growth was +1.68%, and the average quarterly price growth was -9.09%.

Reported Earning Dates

INCR is expected to report earnings on Apr 07, 2025.

SUPN is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.61% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SUPN($1.84B) has a higher market cap than INCR($124M). SUPN has higher P/E ratio than INCR: SUPN (1677.00) vs INCR (22.52). SUPN YTD gains are higher at: 25.155 vs. INCR (10.870). SUPN has higher annual earnings (EBITDA): 90M vs. INCR (25.8M). SUPN has more cash in the bank: 255M vs. INCR (103M). SUPN has less debt than INCR: SUPN (41.5M) vs INCR (163M). SUPN has higher revenues than INCR: SUPN (608M) vs INCR (415M).
INCRSUPNINCR / SUPN
Capitalization124M1.84B7%
EBITDA25.8M90M29%
Gain YTD10.87025.15543%
P/E Ratio22.521677.001%
Revenue415M608M68%
Total Cash103M255M40%
Total Debt163M41.5M393%
FUNDAMENTALS RATINGS
INCR vs SUPN: Fundamental Ratings
INCR
SUPN
OUTLOOK RATING
1..100
1413
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
10043
SMR RATING
1..100
9479
PRICE GROWTH RATING
1..100
5742
P/E GROWTH RATING
1..100
494
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INCR's Valuation (69) in the Servicestothe Health Industry industry is in the same range as SUPN (77) in the Pharmaceuticals Other industry. This means that INCR’s stock grew similarly to SUPN’s over the last 12 months.

SUPN's Profit vs Risk Rating (43) in the Pharmaceuticals Other industry is somewhat better than the same rating for INCR (100) in the Servicestothe Health Industry industry. This means that SUPN’s stock grew somewhat faster than INCR’s over the last 12 months.

SUPN's SMR Rating (79) in the Pharmaceuticals Other industry is in the same range as INCR (94) in the Servicestothe Health Industry industry. This means that SUPN’s stock grew similarly to INCR’s over the last 12 months.

SUPN's Price Growth Rating (42) in the Pharmaceuticals Other industry is in the same range as INCR (57) in the Servicestothe Health Industry industry. This means that SUPN’s stock grew similarly to INCR’s over the last 12 months.

INCR's P/E Growth Rating (4) in the Servicestothe Health Industry industry is significantly better than the same rating for SUPN (94) in the Pharmaceuticals Other industry. This means that INCR’s stock grew significantly faster than SUPN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCRSUPN
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
66%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
62%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 10 days ago
74%
Bullish Trend 3 days ago
73%
Declines
ODDS (%)
Bearish Trend 6 days ago
82%
Bearish Trend about 1 month ago
66%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
70%
View a ticker or compare two or three
Ad is loading...
INCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ELTP0.530.03
+5.71%
Elite Pharmaceuticals, Inc.
BACHY12.270.06
+0.53%
Bank of China, Ltd.
SOUHY10.65-0.08
-0.71%
South32 Ltd.
PEGRY15.11-0.35
-2.26%
Pennon Group PLC
RNMBY128.05-3.50
-2.66%
Rheinmetall AG

INCR and

Correlation & Price change

A.I.dvisor tells us that INCR and KMDA have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INCR and KMDA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCR
1D Price
Change %
INCR100%
N/A
KMDA - INCR
31%
Poorly correlated
-0.86%
SNDL - INCR
25%
Poorly correlated
+4.17%
DVAX - INCR
23%
Poorly correlated
+0.39%
SUPN - INCR
23%
Poorly correlated
-0.74%
QNTM - INCR
23%
Poorly correlated
+1.93%
More

SUPN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SUPN has been loosely correlated with DVAX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if SUPN jumps, then DVAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SUPN
1D Price
Change %
SUPN100%
-0.74%
DVAX - SUPN
33%
Loosely correlated
+0.39%
AMRX - SUPN
30%
Poorly correlated
+4.13%
PBH - SUPN
29%
Poorly correlated
-1.95%
AQST - SUPN
28%
Poorly correlated
+6.94%
SNDL - SUPN
27%
Poorly correlated
+4.17%
More